心房颤动基因筛查的进展及临床应用

洪葵; 苏雨豪

doi:10.13201/j.issn.1001-1439.2023.11.002

心房颤动基因筛查的进展及临床应用

洪葵^1,2,3, ,,
苏雨豪¹

- 1.
  南昌大学第二附属医院心内科(南昌，330006)
- 2.
  南昌大学第二附属医院医学遗传科
- 3.
  江西省分子医学重点实验室

详细信息

通讯作者: 洪葵，E-mail：hongkui88@163.com

中图分类号: R541.7

收稿日期: 2023-10-25

刊出日期: 2023-11-13

Advancements and clinical applications of atrial fibrillation genetic screening

HONG Kui^1,2,3, ,,
SU Yuhao¹

- 1.
  Department of Cardiology, The Second Affiliated Hospital of Nanchang University, Nanchang, 330006, China
- 2.
  Department of Medical Genetic, The Second Affiliated Hospital of Nanchang University
- 3.
  Jiangxi Provincial Key Laboratory of Molecular Medicine

More Information

Corresponding author: HONG Kui, E-mail: hongkui88@163.com

Received Date: 25 October 2023

Publish Date: 13 November 2023

摘要

摘要: 心房颤动(房颤)是一种常见的心律失常，可导致卒中和心力衰竭风险增加，部分呈现遗传易感性。目前家族性房颤患病率尚不清楚，但具有明显的家族聚集性，通常随家族中早发房颤例数的增加而升高。全基因组关联研究发现了百余个与房颤相关的基因位点，其中多数导致离子通道功能障碍和结构重构。本文就房颤基因变异研究、检测方法和临床应用作介绍。
- 心房颤动 /
- 基因筛查 /
- 基因测序
Abstract: Atrial fibrillation is a common cardiac arrhythmia that can increase the risk of stroke and heart failure, and it exhibits a partial genetic susceptibility. Currently, the prevalence of familial atrial fibrillation is not clear, but it shows significant familial clustering, typically increasing with the number of early-onset atrial fibrillation cases within the family. Genome-wide association studies have identified over a hundred genetic loci associated with atrial fibrillation, with most of them leading to ion channel dysfunction and structural remodeling. This article provides an introduction to research on atrial fibrillation gene variants, detection methods, and clinical applications.
- atrial fibrillation /
- genetic screening /
- genetic testing

HTML全文

参考文献(24)

[1]	Roberts R. Mechanisms of disease: Genetic mechanisms of atrial fibrillation[J]. Nat Clin Pract Cardiovasc Med, 2006, 3(5): 276-282. doi: 10.1038/ncpcardio0509
[2]	Darbar D, Herron KJ, Ballew JD, et al. Familial atrial fibrillation is a genetically heterogeneous disorder[J]. J Am Coll Cardiol, 2003, 41(12): 2185-2192. doi: 10.1016/S0735-1097(03)00465-0
[3]	Christophersen IE, Ravn LS, Budtz-Joergensen E, et al. Familial aggregation of atrial fibrillation: a study in Danish twins[J]. Circ Arrhythm Electrophysiol, 2009, 2(4): 378-383. doi: 10.1161/CIRCEP.108.786665
[4]	Fuster V, Rydén LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society[J]. J Am Coll Cardiol, 2011, 57(11): e101-198. doi: 10.1016/j.jacc.2010.09.013
[5]	Yoneda ZT, Anderson KC, Quintana JA, et al. Early-Onset Atrial Fibrillation and the Prevalence of Rare Variants in Cardiomyopathy and Arrhythmia Genes[J]. JAMA Cardiol, 2021, 6(12): 1371-1379. doi: 10.1001/jamacardio.2021.3370
[6]	Goodyer WR, Dunn K, Caleshu C, et al. Broad Genetic Testing in a Clinical Setting Uncovers a High Prevalence of Titin Loss-of-Function Variants in Very Early Onset Atrial Fibrillation[J]. Circ Genom Precis Med, 2019, 12(11): e002713. doi: 10.1161/CIRCGEN.119.002713
[7]	Wilde AAM, Semsarian C, Márquez MF, et al. European Heart Rhythm Association(EHRA)/Heart Rhythm Society(HRS)/Asia Pacific Heart Rhythm Society(APHRS)/Latin American Heart Rhythm Society(LAHRS)Expert Consensus Statement on the State of Genetic Testing for Cardiac Diseases[J]. Heart Rhythm, 2022, 19(7): e1-e60. doi: 10.1016/j.hrthm.2022.03.1225
[8]	Mcnair WP, Ku L, Taylor MR, et al. SCN5A mutation associated with dilated cardiomyopathy, conduction disorder, and arrhythmia[J]. Circulation, 2004, 110(15): 2163-2167. doi: 10.1161/01.CIR.0000144458.58660.BB
[9]	Li Q, Huang H, Liu G, et al. Gain-of-function mutation of Nav1.5 in atrial fibrillation enhances cellular excitability and lowers the threshold for action potential firing[J]. Biochem Biophys Res Commun, 2009, 380(1): 132-137. doi: 10.1016/j.bbrc.2009.01.052
[10]	Chen YH, Xu SJ, Bendahhou S, et al. KCNQ1 gain-of-function mutation in familial atrial fibrillation[J]. Science, 2003, 299(5604): 251-254. doi: 10.1126/science.1077771
[11]	Hong K, Piper DR, Diaz-Valdecantos A, et al. De novo KCNQ1 mutation responsible for atrial fibrillation and short QT syndrome in utero[J]. Cardiovasc Res, 2005, 68(3): 433-440. doi: 10.1016/j.cardiores.2005.06.023
[12]	Hong K, Bjerregaard P, Gussak I, et al. Short QT syndrome and atrial fibrillation caused by mutation in KCNH2[J]. J Cardiovasc Electrophysiol, 2005, 16(4): 394-396. doi: 10.1046/j.1540-8167.2005.40621.x
[13]	Olson TM, Alekseev AE, Liu XK, et al. Kv1.5 channelopathy due to KCNA5 loss-of-function mutation causes human atrial fibrillation[J]. Hum Mol Genet, 2006, 15(14): 2185-2191. doi: 10.1093/hmg/ddl143
[14]	Li RG, Xu YJ, Ye WG, et al. Connexin45(GJC1) loss-of-function mutation contributes to familial atrial fibrillation and conduction disease[J]. Heart Rhythm, 2021, 18(5): 684-693. doi: 10.1016/j.hrthm.2020.12.033
[15]	Orr N, Arnaout R, Gula LJ, et al. A mutation in the atrial-specific myosin light chain gene(MYL4) causes familial atrial fibrillation[J]. Nat Commun, 2016, 7: 11303. doi: 10.1038/ncomms11303
[16]	Hodgson-Zingman DM, Karst ML, Zingman LV, et al. Atrial natriuretic peptide frameshift mutation in familial atrial fibrillation[J]. N Engl J Med, 2008, 359(2): 158-165. doi: 10.1056/NEJMoa0706300
[17]	Kumar S, Baldinger SH, Gandjbakhch E, et al. Long-Term Arrhythmic and Nonarrhythmic Outcomes of Lamin A/C Mutation Carriers[J]. J Am Coll Cardiol, 2016, 68(21): 2299-2307. doi: 10.1016/j.jacc.2016.08.058
[18]	Choi SH, Weng LC, Roselli C, et al. Association Between Titin Loss-of-Function Variants and Early-Onset Atrial Fibrillation[J]. JAMA, 2018, 320(22): 2354-2364. doi: 10.1001/jama.2018.18179
[19]	He J, Zhu W, Yu Y, et al. Variant rs2200733 and rs10033464 on chromosome 4q25 are associated with increased risk of atrial fibrillation after catheter ablation: Evidence from a meta-analysis[J]. Cardiol J, 2018, 25(5): 628-638. doi: 10.5603/CJ.a2017.0143
[20]	中华医学会心电生理和起搏分会, 中国医师协会心律学专业委员会, 中国房颤中心联盟心房颤动防治专家工作委员会. 心房颤动: 目前的认识和治疗建议(2021)[J]. 中华心律失常学杂志, 2022, 26(1): 15-88.
[21]	Kowalski MH, Qian H, Hou Z, et al. Use of>100, 000 NHLBI Trans-Omics for Precision Medicine(TOPMed)Consortium whole genome sequences improves imputation quality and detection of rare variant associations in admixed African and Hispanic/Latino populations[J]. PLoS Genet, 2019, 15(12): e1008500. doi: 10.1371/journal.pgen.1008500
[22]	Yoneda ZT, Anderson KC, Ye F, et al. Mortality Among Patients With Early-Onset Atrial Fibrillation and Rare Variants in Cardiomyopathy and Arrhythmia Genes[J]. JAMA Cardiol, 2022, 7(7): 733-741. doi: 10.1001/jamacardio.2022.0810
[23]	Mulatero P, Monticone S, Deinum J, et al. Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension[J]. J Hypertens, 2020, 38(10): 1919-1928. doi: 10.1097/HJH.0000000000002510
[24]	Mulatero P, Sechi LA, Williams TA, et al. Subtype diagnosis, treatment, complications and outcomes of primary aldosteronism and future direction of research: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension[J]. J Hypertens, 2020, 38(10): 1929-1936. doi: 10.1097/HJH.0000000000002520